Present CEO, Niklas Ahlborg, will remain at the company as a Senior Advisor.
This investment builds on a long-standing collaboration in biocontrol and pollination which began in 1992.
The business purpose of the new joint venture is to promote Ceva’s image and business strategy to potential Japanese partners.
The goal of Oncode-PACT is to create a state-of-the-art drug development infrastructure to innovate the cancer drug development process itself.
Ceva acquired the veterinary biopharmaceutical and R&D activities of IDT Biologika based at the Dessau site in 2019.
The Initiative Climat International is a collective commitment to reduce carbon emissions of private markets-backed companies and secure sustainable...
The EHCPEA is a not-for-profit organization established to promote a better understanding of healthcare private equity to enable their members to...
TARA's state-of-the-art in vitro human cardiac disease models combined with Valo's artificial intelligence-driven Opal platform – which is built on...
Xermelo® is indicated for the treatment of carcinoid syndrome diarrhoea (CSD) in combination with somatostatin analogue (SSA) therapy in adults...
